Advanced image analysis firm QUIBIM's Precision software has been designated as the primary platform for the PARENCHIMA initiative -- a project aimed at bolstering the use of MRI biomarkers for the management of chronic kidney disease.
Launched in April 2017, the PARENCHIMA initiative has sought to develop new standards for the acquisition and analysis of kidney MRI scans. The project's researchers, from 25 different European countries, will centralize medical imaging data and artificial intelligence algorithms using the QUIBIM Precision image analysis platform.
